intratumorally or systemically administering to the subject in need thereof an effective amount of a fusogenic mutant Herpes Simplex Virus Type 2 , wherein the fusogenic mutant {TAIL ~ HSV} 2 comprises a modified ICP10 coding region lacking nucleotides 1 to 1204 of an endogenous ICP10 coding region, wherein said fusogenic mutant HSV 2 comprises {HEAD ~ the modified ICP10} operably linked to an endogenous or a constitutive promoter and expresses a modified ICP10 polypeptide that lacks protein kinase activity but retains ribonucleotide reductase activity, and 
intratumorally or systemically administering to the subject in need thereof an effective amount of a fusogenic mutant Herpes Simplex Virus Type 2 , wherein the fusogenic mutant { TAIL ~ HSV } 2 comprises a modified ICP10 coding region lacking nucleotides 1 to 1204 of an endogenous ICP10 coding region , wherein said fusogenic mutant HSV 2 comprises { HEAD ~ the modified ICP10 } operably linked to an endogenous or a constitutive promoter and expresses a modified ICP10 polypeptide that lacks protein kinase activity but retains ribonucleotide reductase activity , and
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH